1 Age- and sex- differences in efficacy of treatments for 2 type 2 diabetes: Network meta-analysis of aggregate 3 and individual level data

- 31 Dr Peter Hanlon
- 32 Clarice Pears Building,
- 33 University of Glasgow,
- 34 Byres Road,
- 35 Glasgow,
- 36 United Kingdom
- 37
- Peter.hanlon@glasgow.ac.uk

39 Abstract

40 Importance

- 41 Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor
- 42 analogues (GLP1ra) and dipeptidyl peptidase-4 inhibitors (DPP4i) improve hyperglycaemia
- 43 and, in the case of SGLT2i and GLP1ra, reduce the risk of major adverse cardiovascular
- 44 events (MACE) in type 2 diabetes. It is not clear whether efficacy varies by age or sex.

45 Objective

- 46 Assess whether age or sex are associated with differences in efficacy of SGL2i, GLP1ra and
- 47 DPP4i.

48 Data sources

49 Medline, Embase and clinical trial registries.

50 Study selection
51 Two independent revie

- Two independent reviewers screened for randomised controlled trials of
- 52 SGLT2i/GLP1ra/DPP4i, compared to placebo/active comparator, in adults with type 2
- 53 diabetes.

54 Data extraction and synthesis

- 55 We sought individual participant data (IPD) all eligible studies. Where IPD were available, we
- 56 modelled age- and sex-treatment interactions for each trial. Otherwise, we assessed age-
- 57 sex distributions along with results from aggregate trial data. IPD and aggregate findings
- 58 were combined in a Bayesian network meta-analysis.

59 Main outcome measures

60 HbA1c and MACE.

61 Results

- 62 We identified 616 eligible trials (604 reporting HbA1c, 23 reporting MACE) and obtained IPD
- 63 for 75 trials (6 reporting MACE). Mean age was 59.0 (10.7) years and 64.0 (8.6) in HbA1c
- 64 and MACE trials, respectively. Proportions of female were 43.1% and 44.0% in HbA1c and
- 65 MACE trials, respectively. SGLT2i reduced HbA1c by 0.5-1.0% overall compared to placebo.

- 66 This reduction versus placebo was attenuated in older participants (change in HbA1c 0.25
- 67 percentage-points less for 75-year-olds compared to 45-year-olds). SGLT2i showed greater
- 68 relative efficacy in MACE risk reduction among older than younger people. This finding was
- 69 sensitive to the exclusion of one of the IPD MACE trials, however, in all sensitivity analyses,
- 70 SGLT2i were either as efficacious or more efficacious in older participants. There was no
- 71 consistently significant difference in efficacy by age for GLP1ra or DPP4i for HbA1c or
- 72 MACE, nor were there consistent significant sex differences for any class.

73 Conclusion

- 74 Newer glucose-lowering drugs are efficacious across age and sex groups. SGLT2i are more
- 75 cardioprotective in older than younger people despite smaller HbA1c reductions. Age alone
- 76 should not be a barrier to treatments with proven cardiovascular benefit providing they are
- 77 well tolerated align with patient priorities.

78

80 Introduction

81 Over the past two decades, newer glucose lowering agents have transformed the 82 management of type 2 diabetes. The efficacy of agents such as SGLT2 inhibitors (SGLT2i) 83 and GLP1 receptor agonists (GLP1ra) in reducing cardiovascular and kidney outcomes is 84 now well established,^{1,2} leading to their widespread use in clinical practice and prominence 85 in clinical guidelines.³ Questions remain, however, over how to optimise treatment decisions 86 for individuals, including how characteristics such as age and sex might influence treatment 87 recommendations.⁴⁻⁶

88 Almost half of those with type 2 diabetes are aged over 65 years.⁵ Moreover, age-related 89 functional limitations and conditions such as frailty typically manifest earlier in people with 90 type 2 diabetes.⁷ The risk of complications of diabetes increases with age, potentially 91 increasing the absolute benefits of treatment. Conversely, older adults may also be more 92 susceptible to harms of intensive glycaemic targets.^{8,9} Among women, absolute risk of type 2 93 diabetes and cardiovascular disease are lower than in men, but diabetes is associated with 94 a greater relative increase in cardiovascular risk in women than men.^{10,11} Women also have 95 different patterns of cardiovascular complications and less intensive management of 96 cardiovascular risk factors from men.¹² It if therefore important for clinicians, patients and 97 policy makers to understand whether and how responses to treatment differ by age and sex. 98 Clinical guidelines do not currently recommend different treatments for men and women, nor 99 across different age-groups. They have, however, highlighted the uncertainty that comes 100 from the under-representation of women and older people within trials. $3,13$ 101 Addressing this uncertainty is challenging. Analyses of variation in treatment effects using 102 individual trials (even where there is access to individual-level data) often lacks statistical 103 power.¹⁴ Although meta-analyses increase power to detect differences in efficacy across

104 participant characteristics, they can produce misleading results due to aggregation bias, that

105 is, making improper inferences about units of analysis (the individual patient) that were not

- 106 actually analysed.¹⁵ Individual participant data (IPD) meta-analyses, which pool individual-
- 107 level data from multiple trials, largely overcome both these deficiencies, but due to legal and
- 108 practical constraints it is rarely possible to obtain IPD for all relevant trials, limiting gains in
- 109 power and increasing the risk of selection bias.
- 110 We aimed to address these problems via a systematic review and meta-analysis of both
- 111 aggregate and IPD trial data. Using a meta-analysis technique not susceptible to
- 112 aggregation bias, we estimated whether the efficacy of newer glucose lowering medications
- 113 for type 2 diabetes differs according to age and sex.

114 Methods

- 115 This systematic review and network meta-analysis followed a prespecified protocol
- 116 (PROSPERO:CRD42020184174).¹⁶ The protocol covers a wider project for calibration of the
- 117 network meta-analysis to a community sample. This manuscript presents findings from the
- 118 assessment of age- and sex-treatment interactions (prior to calibration). Findings are
- 119 reported according to Preferred Reporting In Systematic Reviews and Meta-analyses
- 120 (PRISMA) guidelines.¹⁷

121 Eligibility criteria and search strategy
122 Eligible studies were randomised trials that recruited a

- Eligible studies were randomised trials that recruited adults (\geq 18 years) with type 2 diabetes,
- 123 and which assessed efficacy of either SGLT2i, GLP1ra , or DPP4 inhibitors (DPP4i) on
- 124 either glycated haemoglobin (HbA1c) or major adverse cardiovascular events (MACE,
- 125 defined as death from cardiovascular causes, non-fatal myocardial infarction or non-fatal
- 126 stroke) compared with either placebo or an active comparator of any other drug class. We
- 127 excluded within-class comparisons and trials that were not registered.
- 128 We searched two electronic databases (Medline and Embase) using both keywords and
- 129 Medical Subject Headings (full search terms shown in the appendix) as well as the United
- 130 States and Chinese clinical trial registries. All titles and abstracts were screened, retaining all
- 131 potentially eligible studies for full text review. All stages of screening were completed by two
- 132 reviewers working independently, with conflicts resolved by consensus and involving a third
- 133 reviewer where required.
- 134 For all eligible trials, we assessed whether IPD were available for analysis by third party
- 135 researchers through the Vivli repository, and applied to the independent steering committee
- 136 for access where this was the case.

137 Data extraction

- 138 Drug names, doses and regimens were extracted from text strings obtained from
- 139 clinicaltrials.gov and published documents (papers and clinical study reports). Age and sex
- 140 at baseline were obtained from published documents. HbA1c results were extracted from
- 141 clinicaltrials.gov where available or published documents if not. For MACE, results were
- 142 obtained via manual extraction from published documents (including age- and sex-
- 143 subgroups). For IPD trials, data were cleaned and harmonised in the Vivli repository.
- 144 We assessed risk of bias in each study using the Cochrane Risk of Bias tool.¹⁸

145 Statistical analysis

- 146 Detailed description of the statistical analysis is in the supplementary appendix, and
- 147 summarised briefly here. All data (IPD-summaries and aggregate level) are available at the
- 148 project github repository
- 149 https://github.com/Type2DiabetesSystematicReview/nma_agesex_public .

150 First, we summarised the age- and sex- distribution for each trial using IPD where available,

151 or from published summary statistics otherwise. Then, for each outcome (HbA1c and MACE)

152 we fitted multilevel network meta-regression (ML-NMR) models using the multinma package

- 153 in R.¹⁹ These models are described in more detail in our protocol paper and in more
- 154 technical detail in the original methods paper.^{16,19} This modelling approach was chosen as i)
- 155 it does not disrupt randomisation ii) it makes less stringent assumptions than standard NMA
- 156 and iii) it can (without causing aggregation bias) accommodate IPD, aggregate-level trial
- 157 data and subgroup-level trial data in models estimating treatment-covariate interactions.
- 158 For HbA1c, we separately fit network meta-analyses for trials of mono-, dual- and triple-
- 159 therapy, reflecting different indications for the drugs in question. All MACE trials were in
- 160 people already established on treatment. We dropped treatment arms evaluating the

161 combined effect of two or more treatments. For the SGLT2i, GLP1ra, DPP4i and metformin, 162 treatment arms were uniquely identified using drug and dose. Insulin, in which dose is 163 titrated, was modelled as a single category. For the remaining drug classes, arms within the 164 same trial with different doses but the same drug were collapsed into a single arm. For all 165 models, placebo was the reference treatment.

166 In trials for which we had IPD, we fitted trial-level regression models of each outcome by 167 age, sex and treatment, as well as assessing age-treatment and sex-treatment interactions. 168 For HbA1c we fitted linear regression models (additionally including HbA1c at baseline as a 169 covariate). Where participants did not complete the trial we carried forward the last recorded 170 value. For the MACE outcomes we fitted Cox regression models. We checked proportional 171 hazards assumption by plotting scales Schofield residuals. These IPD estimates were then 172 meta-analysed along with aggregate trial-level and (for MACE) subgroup-level data on trial 173 outcomes and on the age- and sex-distributions of each trial (as described in the 174 supplementary appendix). Placebo was used as the reference category in all models. 175 Models were summarised using the posterior mean and 95% credible interval for both the 176 main effect and both age-treatment and sex-treatment interactions.

177 Results

178 Systematic review results

- 179 We identified 685 eligible trials, of which 616 were included in the network meta-analyses
- 180 (Figure 1). There were a total of 541 aggregate level and 75 IPD trials, including 230,608
- 181 and 75,850 participants, respectively. Trial-level details and risk of bias are shown in the
- 182 online repository.
- 183 Table 1 shows the total number of included trials reporting HbA1c for each class along with
- 184 aggregate baseline characteristics. Characteristics were similar for trials with IPD and those
- 185 with aggregate trials. For trials reporting MACE, trial-level details are shown in table 2. For
- 186 both HbA1c and MACE reporting trials, almost all trial participants were in the 40 to 80 year
- 187 age range, including trials targeted at older people (supplementary figures S1). For trials
- 188 reporting HbA1c where IPD was available, age was similarly distributed.

Figure 1: PRISMA diagram of included studies

192 **Table 1: Trials reporting HbA1c, comparisons and characteristics**

193 194

196

197 Main treatment effects

- 198 The main treatment effects comparing each treatment versus placebo are shown in
- 199 supplementary figure S2 for HbA1c for a standard network meta-analysis without covariates.
- 200 Most treatments reduced HbA1cwith a range of absolute reductions of -0.5% to -1.5%.
- 201 Supplementary figure S3 shows the same analysis for MACE, showing the expected result
- 202 of reduced hazard of MACE for SGLT2i compared to placebo, with null findings for DPP4i
- 203 and for some agents within the GLP1ra class (consistent with trial-level findings for these
- 204 agents which did not show superiority to placebo).

205 Age-treatment and sex-treatment interactions

206 Figure 2 shows the age-treatment and sex-treatment interactions, assessing differences in 207 the efficacy of treatment by age and sex, for HbA1c (panel a) and MACE (panel b). For 208 HbA1c, interactions are on the absolute scale showing change in HbA1c in units of percent. 209 Across all three networks, SGLT2-inhibitors were less efficacious with increasing age; a 30- 210 year increment in age was associated with an attenuation in effect on Hba1c (%) of around 211 0.25 percentage points on the absolute scale (equivalent to about a quarter to half of the 212 overall treatment effect). There was also some evidence of a sex-treatment interaction for 213 HbA1c across networks for SGLT-2 inhibitors, although this was small in magnitude (around 214 0.05 percentage points) and the upper range of the credible intervals included the null. No 215 consistent differences across networks were apparent for any other age-treatment or sex-216 treatment interactions.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.23.24309242;](https://doi.org/10.1101/2024.06.23.24309242) this version posted June 24, 2024. The copyright holder for this preprint

217

Figure 2: Covariate-treatment interactions for HbA1c and MACE: This figure shows the covariate-treatment interaction estimates for age and sex represented as dots, both for a) HbA1c (top panels) and b) MACE (bottom panel). Horizontal lines show the 95% credible interval. Age was modelled as a continuous variable and divided by 30 (so that the coefficient reflects the difference in efficacy over a 30-year age difference). Estimates below the line of no effect (dashed vertical line) indicate that the treatment is more efficacious in older age/in male sex. Estimates above this line indicate the inverse.

- 225 For MACE, there was evidence of greater relative efficacy in older people for SGLT-2i. For
- 226 GLP-1ra, there was some evidence of lower efficacy in older people. There was also some
- 227 evidence of an age-treatment interaction for DPP-4 inhibitors, with higher efficacy in older
- 228 people (however the main effect in this class was null). When modelling sex-treatment
- 229 interactions in MACE trials, DPP-4i appeared to be less efficacious in men, although this
- 230 association was less evident in trials which included sex-subgroup data and absent on
- 231 excluding the sole DPP-4i trial for which we had access to IPD. For GLP-1ra and SGLT-2i
- 232 there was no evidence of any sex-treatment interactions.
- 233 In sensitivity analyses including/excluding age- and sex-subgroup data in the model, and
- 234 dropping each trial in turn, the greater efficacy in older people for SGLT2i persisted whether
- 235 or not age-subgroup data were included in the modelling, but was not found after excluding
- 236 one of the four SGLT2i IPD trials (NCT01131676, EMPA-REG OUTCOME, see

- 238 attenuated effects of SGLT-2i on HbA1c the reduction in the MACE risk was preserved or
- 239 greater in all of the sensitivity analyses.
- 240 Particular caution is needed in interpreting the GLP-1ra and DPP-4i findings for MACE, as
- 241 results differed depending on the inclusion/exclusion of the single trials of each agent for
- 242 which we had IPD (HARMONY NCT02465515 and EXAMINE NCT00968708 for GLP-1ra
- 243 and DPP4i respectively) and/or the inclusion/exclusion of subgroup data (Supplementary
- 244 figure S4).

245 Age and sex-specific effects for MACE trials

- 246 Figure 3 shows the impact of the age-treatment and sex-treatment interactions on the overall
- 247 age- and sex-specific relative efficacy versus placebo for each class.
- 248 Consistent with the findings reported above for DPP-4 inhibitors (that they were not
- 249 efficacious overall compared to placebo, but with some evidence of differential effect by age
- 250 and sex), DPP4i were associated with increased risk of MACE in men and younger women
- 251 but decreased risk in older women. GLP-1ra (which again were inefficacious overall but with
- 252 differential efficacy by sex) were not associated with significant reduction in MACE in men
- 253 and in older people, but were associated with decreased risk of MACE in younger women.
- 254 SGLT2i were associated with lower MACE in older people regardless of sex with equivocal
- 255 findings for people younger than 60 years. For all three classes, however, some caution is
- 256 needed in interpreting findings given the sensitivity of the interaction estimates to the
- 257 inclusion of particular trials. Less equivocally, SGLT-2i were associated with reduced MACE
- 258 in older men and older women.

Figure 3: Relative effects for MACE: This figure is based on a model including all available trials, including sex-subgroup data as well as aggregate data and IPD. It shows age- and sex- specific estimates of the effect of each treatment compared to placebo on the hazard of MACE.

265 Discussion

290 risk of admission to hospital with heart failure and of end-stage kidney disease, with SGLT2i

291 showing superior efficacy for the latter. Harms with treatment were generally class-specific 292 and included genital infections with SGLT2i and gastrointestinal complications with GLP1ra. 293 This previous analysis, however, did not assess heterogeneity by age and sex, and did not 294 include analysis of IPD.

295 One likely explanation for the reduction in glycaemic efficacy of SGLT2i with older age is 296 age-related decline in kidney function. For example, the recent TriMaster study (a double-297 blind three-way crossover study comparing DPP4i with SGLT2i) demonstrated that 298 participants with estimated glomerular filtration rates 60-90 ml/min/1.73m², compared to 299 those >90 ml/min/1.73m², had lower HbA1c on DPP4 inhibitors than SGLT2 inhibitors.²⁰ In 300 this context, it is notable that the reductions in MACE with SGLT2i were greater in older 301 people, despite lower glycaemic efficacy. This highlights the limitation of surrogate outcomes 302 such as HbA1c in determining the risks of harder endpoints such as MACE for which 303 hyperglycaemia is a less important risk factor than hypertension or dyslipidaemia.²¹ The 304 findings also suggest SGLT2i are working to prevent hard outcomes by pathways largely 305 unrelated to conventional risk factors or dysglycemia. Current clinical guidelines recommend 306 less stringent glycaemic targets in older people living with multiple long-term conditions or 307 frailty due to greater risks of adverse events.^{3,22} While caution around pursuing surrogate 308 markers is well founded, this may also lead to clinicians not initiating therapies with other 309 (e.g. cardiovascular) benefits who may have potential to benefit. Our findings highlight the 310 need to also consider cardioprotective effects agents such as SGLT2i (in addition to safety, 311 tolerability and patient's priorities) when agreeing optimal treatment strategies for older 312 people.

313 The primary strength of this analysis is in the use of individual participant data to estimate 314 age- and sex-treatment interactions. This improves statistical power and allows integration of 315 individual participant data and aggregate data within network meta-analysis to preserve 316 randomisation and avoid aggregation bias. We also followed rigorous systematic review

317 methodology to identify eligible studies, and have made all model outputs and analysis code 318 publicly available to facilitate replication of our findings. However, despite the inclusion of a 319 large volume of IPD, this was not available for all trials. Furthermore, the trials for which we 320 did have IPD were not a random sample of the included trials as their availability depended 321 on the data sharing arrangements put in place by the sponsor. We dropped trial arms with 322 multiple drug classes as the software does not allow for explicit modelling of components 323 within arms, and our focus was on class-level interactions. While we assessed glycaemic 324 and cardiovascular efficacy, which are clinically relevant outcomes, our analysis did not 325 include other clinical endpoints (such as kidney events) or analysis of adverse events and 326 safety, which would be relevant outcomes for future analyses.

327 While our findings demonstrate similar or better cardiovascular efficacy among older people 328 within these trials, trials rarely enrol people over 80 years of age. Furthermore, age-

329 associated states such as frailty, which increase the risk of both cardiovascular events and 330 also of complications, $8,23$ are not quantified in these trials. This analysis does not, therefore, 331 assess whether efficacy is similar in people of much higher ages (i.e. over 80 years) or living 332 with frailty. This is a group in which the balance of risks and benefits is most uncertain, and 333 as such several complementary strands of evidence are needed. Retrospective assessment 334 of frailty within trial IPD (e.g. using the cumulative deficit frailty index) can allow assessment 335 of frailty within trial participants,²⁴ but those with most severe frailty are likely to be excluded 336 from the trial altogether. Routine healthcare data may be used to model natural history and 337 rates of complications across a range of ages and health states, allowing modelling of 338 overall benefit. Observational analyses using causal inference methods may also be utilised 339 to assess safety, including in people who may be under-represented in trials. However, 340 biases such as confounding by indication remain a significant challenge in such analyses. 341 Finally, where uncertainty remains, there is a need for trials that recruit and retain older 342 people and those living with frailty, and which explicitly measure and report functional status.

354 Acknowledgements

- 355 Data access and provision: This manuscript is based on research using data from data 356 contributors Lilly, Boehringer Ingelheim, Sanofi, Takeda, GlaxoSmithKline, AstraZeneca and 357 Johnson & Johnson that has been made available through Vivli, Inc. Vivli has not contributed 358 to or approved, and is not in any way responsible for, the contents of this publication.
- 359 Funding: This study was funded by the Medical Research Council (Grant reference
- 360 MR/T017112/1). The funder had no role in the design, conduct or interpretation of the
- 361 analysis. The pharmaceutical companies that provided the data did not provide any funding
- 362 or support to the study and had no role in the design, conduct or interpretation of the
- 363 analysis.
- 364 Author contributions: PH, EB and DM conceived the study. EB, LW and PH performed the
- 365 literature search and screened articles for inclusion. EB, PH, LW, JC, HR, SA and KA
- 366 extracted aggregate data from the included studies. DM, HW, JC, RM and PH accessed and
- 367 processed the individual-level data. DM wrote the statistical analysis plan with DP, SD and
- 368 NW providing statistical input. DM performed the analysis with input from DP, SD, NW and
- 369 PH on analysis outputs. PH wrote the first draft. EB, LW, HW, SA, KA, JC, RM, HR, KH, JL,
- 370 RL, SM, JP, LT, SW, AA, NS, DP, SD, NW and DM reviewed this and subsequent drafts
- 371 providing critical input. All authors approved the final version for submission.
- 372 Data availability: Individual-level participant data was obtained through the Vivli project,
- 373 subject to a data sharing agreement. Data are available on application to the data holder via
- 374 Vivli's application process. All aggregate data, as well as summary data from all analyses of
- 375 individual participant data, are available at
- 376 https://github.com/Type2DiabetesSystematicReview/nma_agesex_public, along with
- 377 analysis code for all the analyses presented in the manuscript and supplementary
- 378 appendices.

379 Declarations of interest

- 380 John Petrie reports personal fees (via his employing institution) from Merck KGaA
- 381 (Lectures), research support from Merck KGaA (Grant), personal fees from Novo Nordisk
- 382 (Lectures/ Advisory) and personal fees from IQVIA (Boehringer Ingelheim Adjudication
- 383 Committees) all outside the submitted work. Dr Petrie has received non-financial support
- 384 as co-CI of a JDRF-funded trial (NCT03899402) from Astra Zeneca (donation of
- 385 investigational medicinal product to US site only) and Novo Nordisk [donation of
- 386 investigational medicinal product to UK site only; supplementary financial support (to
- 387 mitigate a budget cut during the COVID-19 pandemic)].
- 388 Robert Lindsey reports Event registration paid for by Novo Nordisk 2021, no personal fees.
- 389 And is current local PI for SOUL study (Novo Nordisk)- no personal fees.
- 390 Amanda Adler's trials unit is undertaking a trial funded by NovoNordisk. The indication is not
- 391 diabetes.
- 392 Naveed Sattar declares grant funding from AstraZeneca, Boehringer Ingelheim, Novartis,
- 393 and Roche Diagnostics; consulting fees from Abbott Laboratories, AbbVie, Amgen,
- 394 AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-
- 395 Ricerche, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; payment for
- 396 lectures or presentations from Abbott Laboratories, AbbVie, AstraZeneca, Boeringer
- 397 Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and Sanofi. All work was unrelated to this
- 398 manuscript.
- 399 All other authors declare no conflicts of interest.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.23.24309242;](https://doi.org/10.1101/2024.06.23.24309242) this version posted June 24, 2024. The copyright holder for this preprint

400 References

401 1. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 402 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 403 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ* 404 2021; **372**: m4573.

405 2. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 406 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ* 407 2023; **381**: e074068.

408 3. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 409 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the 410 European Association for the Study of Diabetes (EASD). *Diabetes care* 2022; **45**(11): 2753- 411 86.

4. Singh AK, Singh R. Gender difference in cardiovascular outcomes with SGLT-2 413 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-414 analysis of cardio-vascular outcome trials. *Diabetes & Metabolic Syndrome: Clinical* 415 *Research & Reviews* 2020; **14**(3): 181-7.

416 5. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older adults: 417 clinical considerations and management. *Nature Reviews Endocrinology* 2021; **17**(9): 534- 418 48.

419 6. Bellary S, Barnett AH. SGLT2 inhibitors in older adults: overcoming the age barrier.
420 The Lancet Healthy Longevity 2023: 4(4): e127-e8. *The Lancet Healthy Longevity* 2023; **4**(4): e127-e8.

421 7. Hanlon P, Fauré I, Corcoran N, et al. Frailty measurement, prevalence, incidence, 422 and clinical implications in people with diabetes: a systematic review and study-level meta-
423 analysis. The Lancet Healthy Longevity 2020. 423 analysis. *The Lancet Healthy Longevity* 2020.

424 8. Nguyen TN, Harris K, Woodward M, et al. The Impact of Frailty on the Effectiveness 425 and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People 426 With Type 2 Diabetes: Results From the ADVANCE Trial. *Diabetes Care* 2021; **44**(7): 1622- 427 9.

428 9. Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive 429 glucose control on adverse events, cardiovascular disease, and mortality in older versus 430 younger adults in the ACCORD trial. *Diabetes Care* 2014; **37**(3): 634-43.

431 10. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women 432 compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 433 individuals and 12 539 strokes. *The Lancet* 2014; **383**(9933): 1973-80.

434 11. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary 435 heart disease in women compared with men: a systematic review and meta-analysis of 64 436 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* 2014; **57**: 437 1542-51.

438 12. Peters SA, Woodward M. Sex differences in the burden and complications of 439 diabetes. *Current diabetes reports* 2018; **18**: 1-8.

440 13. Clemens KK, Woodward M, Neal B, Zinman B. Sex disparities in cardiovascular 441 outcome trials of populations with diabetes: a systematic review and meta-analysis. *Diabetes* 442 *Care* 2020; **43**(5): 1157-63.

443 14. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup 444 analyses in randomized trials: risks of subgroup-specific analyses;: power and sample size 445 for the interaction test. *Journal of clinical epidemiology* 2004; **57**(3): 229-36.

446 15. Geissbühler M, Hincapié CA, Aghlmandi S, Zwahlen M, Jüni P, da Costa BR. Most 447 published meta-regression analyses based on aggregate data suffer from methodological 448 pitfalls: a meta-epidemiological study. *BMC Medical research methodology* 2021; **21**(1): 123.

449 16. Butterly E, Wei L, Adler AI, et al. Calibrating a network meta-analysis of diabetes 450 trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.23.24309242;](https://doi.org/10.1101/2024.06.23.24309242) this version posted June 24, 2024. The copyright holder for this preprint

451 analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a 452 systematic review protocol. *BMJ open* 2022; **12**(10): e066491.

453 17. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting
454 systematic reviews: development of the PRISMA 2020 statement. Journal of Clinica 454 systematic reviews: development of the PRISMA 2020 statement. *Journal of Clinical* 455 *Epidemiology* 2021; **134**: 103-12.

456 18. Higgins J, Altman D, Sterne J. Assessing risk of bias in included studies. In: Higgins 457 J, Churchill R, Chandler J, Cumpston M, eds. Cochrane Handbook for Systematic Reviews 458 of Interventions version 520 (updated June 2017): Cochrane.

- 459 19. Phillippo DM. multinma: An R package for Bayesian network meta-analysis of 460 individual and aggregate data. Evidence Synthesis and Meta-Analysis in R Conference individual and aggregate data. Evidence Synthesis and Meta-Analysis in R Conference 461 2021; 2021; 2021.
- 20. Shields BM, Dennis JM, Angwin CD, et al. Patient stratification for determining 463 optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. *Nat Med* 464 2023; **29**(2): 376-83.
- 465 21. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. *Bmj* 2011; **343**.
- 466 22. Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert 467 consensus statement on the management of older adults with type 2 diabetes. *Diabetes* 468 *Therapy* 2021; **12**: 1227-47.
- 469 23. Hanlon P, Jani BD, Butterly E, et al. An analysis of frailty and multimorbidity in 20,566
470 UK Biobank participants with type 2 diabetes. Communications Medicine 2021: 1(1): 1-9. 470 UK Biobank participants with type 2 diabetes. *Communications Medicine* 2021; **1**(1): 1-9.
- 471 24. Hanlon P, Butterly E, Lewsey J, Siebert S, Mair FS, McAllister DA. Identifying frailty
- 472 in trials: an analysis of individual participant data from trials of novel pharmacological 473 interventions. *BMC Med* 2020; **18**(1).
-